Article Per Year (5 Year)
p-Index From 2021 - 2026
0
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Ni Luh Putu Rustiari Dewi
RS Universitas Udayana, Jimbaran, Bali, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Hypertrophic Cardiomyopathy Ni Luh Putu Rustiari Dewi
Cermin Dunia Kedokteran Vol 46, No 12 (2019): Kardiovaskular
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i12.393

Abstract

Hypertrophic Cardiomyopathy (HCM) merupakan kelainan jantung primer yang diturunkan secara genetik dengan karakteristik penebalan abnormal jaringan otot terutama ventrikel kiri tanpa kelainan jantung dan sistemik lainnya.Sekitar 60% kasus HCM diturunkan secara autosomal dominan berupa mutasi protein sarkomer jantung. Diagnosis berdasarkan klinis, elektrokardiogram, ekokardiogram, cardiac magnetic resonance (CMR), dan pemeriksaan genetik. Terapi ß-blocker dan penyekat kanal kalsium untuk mengurangi gejala sesak nafas, nyeri dada, penurungan aktivitas fisik. Intervensi invasif dengan ventricular septal myectomy (Morrow procedure) atau alcohol septal ablation. Evaluasi berkala dan konseling genetik juga direkomendasikan termasuk pada pasien tanpa gejala.Hypertrophic cardiomyopathy (HCM) is a primary cardiac disorder characterised by hypertrophy, usually of the left ventricle, in the absence of other conditions. Around 60% HCM patients have an autosomal dominant trait in cardiac sarcomere protein genes mutations. Diagnosis is established by clinical manifestation, electrocardiogram, echocardiogram, or cardiac magnetic resonance (CMR). Genetic test should be considered. Management consists of medications; ß-blocker and calcium channel-blocker are used to treat breathing difficulty, chest pain, decreased activity tolerance or fatigue. Invasive management are ventricular septal myectomy (Morrow procedure) or alcohol septal ablation. Periodic re-evaluation and genetic counseling is recommended, including in asymptomatic patients.
Hypertrophic Cardiomyopathy Ni Luh Putu Rustiari Dewi
Cermin Dunia Kedokteran Vol 46 No 12 (2019): Kardiovakular
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i12.390

Abstract

Hypertrophic cardiomyopathy (HCM) merupakan kelainan jantung primer yang diturunkan secara genetik dengan karakteristik penebalanabnormal jaringan otot terutama ventrikel kiri tanpa kelainan jantung dan sistemik lainnya.Sekitar 60% kasus HCM diturunkan secara autosomal dominan berupa mutasi gen-gen protein sarkomer jantung. Diagnosis ditegakkan berdasarkan klinis, elektrokardiogram, ekokardiogram, atau cardiac magnetic resonance (CMR). Pemeriksaan genetik dapat dipertimbangkan. Terapi ß-blocker dan penyekat kanal kalsium digunakan untuk mengurangi gejala sulit bernapas, nyeri dada, penurunan aktivitas fisik, atau kelelahan. Intervensi invasif dengan ventricular septal myectomy (Morrow procedure) atau alcohol septal ablation. Evaluasi ulang secara berkala dan konseling genetik juga direkomendasikan termasuk pada pasien tanpa gejala. Hypertrophic cardiomyopathy (HCM) is a primary cardiac disorder characterised by abnormal hypertrophy of cardiac muscle, usually of the left ventricle, in the absence of other cardiac or systemic conditions. Around 60% HCM patients have an autosomal dominant trait in cardiac sarcomere protein genes mutations. Diagnosis is established by clinical manifestation, electrocardiogram, echocardiogram, or cardiac magnetic resonance (CMR). Genetic test should be considered. Management consists of medications; ß-blocker and calcium channel-blocker are used to treat breathing difficulty, chest pain, decreased activity tolerance or fatigue. Invasive management are ventricular septal myectomy (Morrow procedure) or alcohol septal ablation. Periodic re-evaluation and genetic counseling is recommended, including in asymptomatic patients.
Hypertrophic Cardiomyopathy Ni Luh Putu Rustiari Dewi
Cermin Dunia Kedokteran Vol 46 No 12 (2019): Kardiovakular
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i12.390

Abstract

Hypertrophic cardiomyopathy (HCM) merupakan kelainan jantung primer yang diturunkan secara genetik dengan karakteristik penebalanabnormal jaringan otot terutama ventrikel kiri tanpa kelainan jantung dan sistemik lainnya.Sekitar 60% kasus HCM diturunkan secara autosomal dominan berupa mutasi gen-gen protein sarkomer jantung. Diagnosis ditegakkan berdasarkan klinis, elektrokardiogram, ekokardiogram, atau cardiac magnetic resonance (CMR). Pemeriksaan genetik dapat dipertimbangkan. Terapi ß-blocker dan penyekat kanal kalsium digunakan untuk mengurangi gejala sulit bernapas, nyeri dada, penurunan aktivitas fisik, atau kelelahan. Intervensi invasif dengan ventricular septal myectomy (Morrow procedure) atau alcohol septal ablation. Evaluasi ulang secara berkala dan konseling genetik juga direkomendasikan termasuk pada pasien tanpa gejala. Hypertrophic cardiomyopathy (HCM) is a primary cardiac disorder characterised by abnormal hypertrophy of cardiac muscle, usually of the left ventricle, in the absence of other cardiac or systemic conditions. Around 60% HCM patients have an autosomal dominant trait in cardiac sarcomere protein genes mutations. Diagnosis is established by clinical manifestation, electrocardiogram, echocardiogram, or cardiac magnetic resonance (CMR). Genetic test should be considered. Management consists of medications; ß-blocker and calcium channel-blocker are used to treat breathing difficulty, chest pain, decreased activity tolerance or fatigue. Invasive management are ventricular septal myectomy (Morrow procedure) or alcohol septal ablation. Periodic re-evaluation and genetic counseling is recommended, including in asymptomatic patients.
Co-Authors